Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>> Download now...

Biotech in China
Biotech in China

Free from Nature

>> Download now...

EntreMed Raises $10 Million from China-Connected Investors

publication date: Jan 23, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed, a clinical stage US biotech, landed $10 million from a group of investors with China roots. The investors included Tak W. Mak, PhD, a renowned cancer scientist who discovered EntreMed’s leading drug candidate, ENMD-2076. Dr. Mak is a previous investor in EntreMed and is also a part of a company that owns the China rights to ENMD-2076. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners